Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2024

01-04-2024 | Gilteritinib | Case Report

Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report

Authors: Jiawen Wang, Han Zhu, Kourong Miao

Published in: Annals of Hematology | Issue 5/2024

Login to get access

Abstract

Pure red cell aplasia (PRCA) is a rare bone marrow (BM) disorder characterized by ineffective erythropoiesis, reduced reticulocyte count, normocytic anemia, and the absence of erythroid precursors. Here, we present a rare instance of PRCA occurring after ABO-matched allo-HSCT in a refractory/relapsed acute myeloid leukemia (R/R AML) patient. In this case, the patient received a combination treatment of Gilteritinib, Venetoclax, and Azacitidine. Remarkably, this treatment not only reduced myeloblasts but also facilitated the restoration of erythroid hematopoiesis.
Literature
1.
2.
Longval T et al (2021) Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol 193(4):814–826CrossRefPubMed
3.
Jung SH et al (2012) Successful treatment of pure red cell aplasia with Rituximab in patients after ABO-Compatible allogeneic hematopoietic stem cell transplantation. Case Rep Oncol 5(1):110–113CrossRefPubMedPubMedCentral
4.
Salas MQ, Alahmari A, Lipton JH (2020) Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol 104(2):145–147CrossRefPubMed
5.
Marco-Ayala J et al (2021) Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question. Bone Marrow Transpl 56(4):769–778CrossRef
6.
Chapuy CI et al (2018) Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med 379(19):1846–1850CrossRefPubMed
7.
Roychowdhury DF, Linker CA (1995) Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transpl 16(3):471–472
8.
Saunthararajah Y et al (2003) Effects of 5-aza-2’-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102(12):3865–3870CrossRefPubMed
Metadata
Title
Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report
Authors
Jiawen Wang
Han Zhu
Kourong Miao
Publication date
01-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05714-y

Other articles of this Issue 5/2024

Annals of Hematology 5/2024 Go to the issue

Original Article

Epidemiological features and a survival nomogram for primary lymphoma of the male genital tract

Original Article

Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection

Original Article

Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation

Original Article

The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients

Research

Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population

Research

Impact of BK polyomavirus viremia on the outcomes of allogeneic hematopoietic stem cell transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits